Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are ...

Novo Nordisk has started building its first brand-new manufacturing facility in Denmark since the millennium, saying it plans to spend around DKK 8.5 billion ($1.2 billion) on the plant.

Wegovy and Ozempic remain on the FDA's shortages list, despite strenuous efforts by Novo Nordisk to ramp up its production capacity ... What's Possibl In a new white paper from the World Without ...

It’s been another busy year in Indiana health care and life sciences, with headlines nearly every week announcing another ...

In the last 125 years, only one of the 21 Democrats serving North Carolina as governor faced the same challenge as Roy Cooper ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Novo Nordisk recently announced results for a new weight loss candidate, CagriSema. Data from the trial underwhelmed investors, and Novo stock is down almost 20% on the news. However, investors ...

Novo Nordisk (NVO) closed at $85.73 in the latest trading session, marking a -1.88% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 1.07% for the day.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors ... Bagsværd, Denmark-based Novo Nordisk is a global healthcare company and ...

Danish pharmaceutical leader Novo Nordisk (NYSE: NVO ... results from a phase 3 clinical trial surrounding one of its new GLP-1 candidates, called CagriSema. The name CagriSema is simply an ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...